RED:1,2,3 as per NICE TA180 for psoriasis
RED:1,2,3 NICE TA340 for treating active psoriatic arthritis. (Decision date - July 2015)
RED1,2,3: NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. (Decision date - August 2017)
RED1,2,3: NICE TA456: ustekinumab for moderately to severely active Crohn's Disease after previous treatment.
RED 1,2,3: NICE TA633: ustekinumab for moderately to severely active ulcerative colitis (Decision date - July 2020)